Department of Radio-Oncology, Clinique de Genolier, Genolier 4 route du Muids, Switzerland.
Breast. 2010 Feb;19(1):23-7. doi: 10.1016/j.breast.2009.10.008. Epub 2009 Nov 13.
Enormous efforts are currently put forth in translational breast cancer research. These efforts are directed to both the development of new drugs and the implementation of novel techniques of local treatment, including radiotherapy. This latter discipline is actually a particularly fertile ground for translational research, since scientists and clinicians are developing novel tools in biology and radiation physics, which reduce the gap between the lab and the clinic, and identify innovative strategies that one didn't even dream, only a few years ago. Nowadays the most recent advances in translational breast cancer research are articulated, in radiation science, around three main domains, namely molecular biology, experimental models for tumour growth and response to treatment, and mechanisms underlying levels of malignant and normal cell radio-sensitivity/radio-resistance. In an attempt to put into perspective what could be the breast cancer radiotherapy of the next decade, these three domains are reviewed and discussed in the present article, at the light of ongoing, "from bench to bedside" studies.
目前，在转化乳腺癌研究方面投入了巨大的努力。这些努力旨在开发新药和实施新的局部治疗技术，包括放射治疗。后一学科实际上是转化研究的一个特别肥沃的领域，因为科学家和临床医生正在生物学和放射物理学领域开发新工具，这些工具缩小了实验室和临床之间的差距，并确定了创新策略，这些策略甚至在几年前都还无法想象。如今，转化乳腺癌研究的最新进展在放射科学中主要围绕三个领域展开，即分子生物学、肿瘤生长和治疗反应的实验模型，以及恶性和正常细胞放射敏感性/放射抗性的机制。为了展望未来十年的乳腺癌放射治疗，本文综述并讨论了这三个领域，结合正在进行的“从基础到临床”研究。
